Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

BACKGROUND The US Food and Drug Administration solicited evidence-based recommendations to improve guidance for studies of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). METHODS We analyzed 7 HABP/VABP datasets to explore novel noninferiority study endpoints and designs, focusing on alternatives to all-cause mortality (ACM). RESULTS ACM at day 28 differed for ventilated HABP (27.8%), VABP (18.0%), and nonventilated HABP (14.5%). A "mortality-plus" (ACM+) composite endpoint was constructed by combining ACM with patient-relevant, infection-related adverse events from the Medical Dictionary for Regulatory Activities toxic/septic shock standardized query. The ACM+ rate was 3-10 percentage points above that of ACM across the studies and treatment groups. Predictors of higher ACM/ACM+ rates included older age and elevated acute physiology and chronic health evaluation (APACHE) II score. Only patients in the nonventilated HABP group were able to report pneumonia symptom changes. CONCLUSIONS If disease groups and patient characteristics in future studies produce an ACM rate so low (<10%-15%) that a fixed noninferiority margin of 10% cannot be justified (requiring an odds ratio analysis), an ACM+ endpoint could lower sample size. Enrichment of studies with patients with a higher severity of illness would increase ACM. Data on symptom resolution in nonventilated HABP support development of a patient-reported outcome instrument.

• Publication year

  2019

• Venue

  Journal of Infectious Diseases

• Publication date

  2019-01-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/infdis/jiy578PMID 30649434PMCID PMC6562159
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Progress in the Fight Against Multidrug-Resistant Bacteria 2005–2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance

  2017cited by this paper
• Patient-Reported Outcome Assessments as Endpoints in Studies in Infectious Diseases.

  2016cited by this paper
• Developing Outcomes Assessments as Endpoints for Registrational Clinical Trials of Antibacterial Drugs: 2015 Update From the Biomarkers Consortium of the Foundation for the National Institutes of Health.

  2016cited by this paper
• Development Of A New Patient Reported Outcome (PRO) Measure For Community-Acquired Bacterial Pneumonia (CABP)

  2014cited by this paper
• Randomized Phase 2 Trial To Evaluate the Clinical Efficacy of Two High-Dosage Tigecycline Regimens versus Imipenem-Cilastatin for Treatment of Hospital-Acquired Pneumonia

  2013cited by this paper
• A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia

  2012cited by this paper
• Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study.

  2012cited by this paper
• Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health.

  2012cited by this paper
• Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens

  2011cited by this paper
• Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.

  2010cited by this paper
• Nosocomial pneumonia in the intensive care unit acquired by mechanically ventilated versus nonventilated patients.

  2010cited by this paper
• Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study.

  2008cited by this paper
• Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study*

  2008cited by this paper
• Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study*

  2008cited by this paper
• Good Enough: A Primer on the Analysis and Interpretation of Noninferiority Trials

  2006cited by this paper
• Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.

  2003cited by this paper

• Individual target pharmacokinetic/pharmacodynamic attainment rates among cefepime-treated patients admitted to the ICU with hospital-acquired pneumonia with and without ECMO

  2025cites this paper
• Prognostic Impact of Early Appropriate Antimicrobial Therapy in Critically Ill Patients With Nosocomial Pneumonia Due to Gram-Negative Pathogens: A Multicenter Cohort Study

  2025cites this paper
• The JRS guideline for the management of pneumonia in adults 2024.

  2025cites this paper
• Single-drug versus combination antimicrobial therapy in critically ill patients with hospital-acquired pneumonia and ventilator-associated pneumonia due to Gram-negative pathogens: a multicenter retrospective cohort study

  2024cites this paper
• Hospital-acquired bacterial pneumonia in critically ill patients: from research to clinical practice

  2024cites this paper
• Automated Analysis and Optimization Strategies for University Financial Budget Management Based on Big Data

  2024cites this paper
• Win Ratio Analyses of Piperacillin-Tazobactam Versus Meropenem for Ceftriaxone-Nonsusceptible Escherichia coli or Klebsiella pneumoniae Bloodstream Infections: Post Hoc Insights From the MERINO Trial

  2024cites this paper
• Perspectives on the use of ceftolozane/tazobactam: a review of clinical trial data and real-world evidence

  2024cites this paper
• An Adjudication Protocol for Severe Pneumonia

  2023influential citation
• Antimicrobial Resistance in Ventilator-Associated Pneumonia: Predictive Microbiology and Evidence-Based Therapy

  2023cites this paper
• Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression Analysis

  2023cites this paper
• Determinants of Mortality for Ventilated Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia

  2023cites this paper
• Management of pneumonia in the critically ill.

  2023cites this paper
• Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial

  2023cites this paper
• Machine learning to identify risk factors associated with the development of ventilated hospital-acquired pneumonia and mortality: implications for antibiotic therapy selection

  2023cites this paper
• Individual meropenem epithelial lining fluid and plasma PK/PD target attainment

  2023cites this paper
• Resistance in Pseudomonas aeruginosa: A Narrative Review of Antibiogram Interpretation and Emerging Treatments

  2023cites this paper
• Moving beyond mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.

  2023cites this paper
• Non-ventilator-associated ICU-acquired pneumonia (NV-ICU-AP) in patients with acute exacerbation of COPD: From the French OUTCOMEREA cohort

  2023cites this paper
• Severe infections caused by difficult-to-treat Gram-negative bacteria

  2023influential citation
• Assessment of Nosocomial Pneumonia Antibiotic Susceptibility Patterns among Patients in Intensive Care Units

  2023cites this paper
• Exposure–Efficacy Analyses Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Participants with Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia in ASPECT-NP

  2022cites this paper
• Novel investigational treatments for ventilator-associated pneumonia and critically ill patients in the intensive care unit

  2022cites this paper
• Treatment of ventilator-associated pneumonia due to carbapenem-resistant Gram-negative bacteria with novel agents: a contemporary, multidisciplinary ESGCIP perspective

  2022cites this paper
• Inappropriate Empiric Therapy Impacts Complications and Hospital Resource Utilization Differentially Among Different Types of Bacterial Nosocomial Pneumonia: A Cohort Study, United States, 2014–2019

  2022cites this paper
• Cost-utility analysis of ceftolozane/tazobactam vs meropenem in patients with hospital-acquired pneumonia (HABP) or ventilator-associated pneumonia (VABP)

  2022cites this paper
• Ceftolozane-tazobactam in nosocomial pneumonia

  2022cites this paper
• Efficacy and safety of tedizolid for the treatment of ventilated gram-positive hospital-acquired or ventilator-associated bacterial pneumonia in Japanese patients: Results from a subgroup analysis of a phase 3, randomized, double-blind study comparing tedizolid and linezolid.

  2022cites this paper
• Improving Traditional Registrational Trial Endpoints: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Complicated Urinary Tract Infection Clinical Trials.

  2022cites this paper
• Carbapenem-resistant Pseudomonas aeruginosa: an assessment of frequency of isolation from ICU versus non-ICU, phenotypic and genotypic profiles in a multinational population of hospitalized patients

  2022cites this paper
• New antibiotics for Gram-negative pneumonia

  2022cites this paper
• Analisi di costo-utilità di ceftolozano/tazobactam rispetto a meropenem in pazienti con polmonite acquisita in ospedale (HABP) o polmonite associata a ventilazione meccanica (VABP)

  2022cites this paper
• Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia.

  2022cites this paper
• Ventilator-associated pneumonia

  2022cites this paper
• Systematic Literature Review of Real-world Evidence of Ceftolozane/Tazobactam for the Treatment of Respiratory Infections

  2021cites this paper
• Hospital-Acquired Pneumonia: The Lebanese Societies for Pulmonary, Critical Care, and Infectious Diseases and Clinical Microbiology Joint Guidelines

  2021cites this paper
• Cost Effectiveness of Ceftolozane/Tazobactam Compared with Meropenem for the Treatment of Patients with Ventilated Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

  2021cites this paper
• Pneumonia

  2021cites this paper
• A Phase 3, Randomized, Double-Blind Study Comparing Tedizolid Phosphate and Linezolid for Treatment of Ventilated Gram-Positive Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia

  2021cites this paper
• Descriptive Epidemiology and Outcomes of Nonventilated Hospital-Acquired, Ventilated Hospital-Acquired, and Ventilator-Associated Bacterial Pneumonia in the United States, 2012–2019

  2021cites this paper
• Choosing and changing the analysis scale in non-inferiority trials with a binary outcome

  2021influential citation
• Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia

  2021cites this paper
• Efficacy and appropriateness of novel antibiotics in response to antimicrobial-resistant gram-negative bacteria in patients with sepsis in the ICU

  2021cites this paper
• Management of pneumonia in critically ill patients

  2021cites this paper
• Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial

  2021cites this paper
• Is ventilated hospital-acquired pneumonia a worse entity than ventilator-associated pneumonia?

  2020cites this paper
• Achieving Regulatory Alignment for Anti-Infective Clinical Trials.

  2020cites this paper
• Contributing Factors to the Clinical and Economic Burden of Patients with Laboratory-Confirmed Carbapenem-Nonsusceptible Gram-Negative Respiratory Infections

  2020cites this paper
• Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia

  2020cites this paper
• Antimicrobial Stewardship: Fighting Antimicrobial Resistance and Protecting Global Public Health

  2020cites this paper
• 25th International Symposium on Infections in the Critically Ill Patient

  2020cites this paper
• Trends in hospital-acquired and ventilator-associated bacterial pneumonia trials.

  2020cites this paper
• Outcomes in Participants with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane/Tazobactam Treatment of Nosocomial Pneumonia (ASPECT-NP)

  2020cites this paper
• Hospital-Acquired Pneumonia. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) Guidelines. 2019 Update.

  2020cites this paper
• A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)

  2020cites this paper
• Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Dose Selection for ME1100, an Arbekacin Inhalation Solution

  2020cites this paper
• The Foundation for the National Institutes of Health Biomarkers Consortium: Past Accomplishments and New Strategic Direction

  2019cites this paper
• Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.

  2019cites this paper
• Non-inferiority versus Superiority for New Antibiotics in an Era of High Antimicrobial Resistance: the case for post-marketing Adaptive Randomized Controlled Trials AUTHORS: *MD

  2019cites this paper
• Non-inferiority versus superiority trial design for new antibiotics in an era of high antimicrobial resistance: the case for post-marketing, adaptive randomised controlled trials.

  2019cites this paper
• The Infectious Diseases Society of America's 10 × '20 Initiative (10 New Systemic Antibacterial Agents US Food and Drug Administration Approved by 2020): Is 20 × '20 a Possibility?

  2019cites this paper
• Ceftolozane/tazobactam versus meropenem in patients with Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: Subset analysis ventilated hospital-acquired bacterial pneumonia: Subset analysis of the ASPECT-NP randomized, controlled phase 3 trial

  year unknowninfluential citation